Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. [PDF]
PLoS Pathogens, 2023 BackgroundThis study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in primarily vaccinated volunteers with two doses of ChAdOx1-S or BBIBP-CorV.Materials ...
Sana Eybpoosh +14 more
doaj +4 more sources
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report [PDF]
Vaccines, 2021 Real-life data on the performance of vaccines against SARS-CoV-2 are still limited. We here present the rates of detection and levels of antibodies specific for the SARS-CoV-2 spike protein RBD (receptor binding domain) elicited by four vaccines ...
Olivera Lijeskić +6 more
doaj +3 more sources
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 [PDF]
Frontiers in Medicine, 2023 BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these ...
Enikő Szabó +19 more
doaj +10 more sources
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial [PDF]
Signal Transduction and Targeted Therapy, 2022 The increased coronavirus disease 2019 (COVID-19) breakthrough cases pose the need of booster vaccination. We conducted a randomised, double-blinded, controlled, phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost ...
Nawal Al Kaabi +37 more
doaj +2 more sources
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial [PDF]
Signal Transduction and Targeted Therapy, 2023 An ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate, named NVSI-06-09, as a booster dose in subjects aged 18 years and older from the United ...
Nawal Al Kaabi +56 more
doaj +2 more sources
Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka. [PDF]
Immunology, 2022 As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV in different populations, antibody responses against different SARS-CoV-2 variants of concern and T cell responses, we investigated the immunogenicity of the vaccine, in ...
Jeewandara C +31 more
europepmc +3 more sources
Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine [PDF]
Diagnostics, 2023 Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in ...
Éva Rákóczi +5 more
doaj +2 more sources
Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines [PDF]
Vaccines, 2023 The course of the COVID-19 pandemic has been critically altered by the availability of vaccines. To assess the risk of COVID-19 in the vaccinated, as compared to the unvaccinated population, as well as the comparative effectiveness of the BBIBP-CorV ...
Zoran Kokić +2 more
doaj +3 more sources
Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study [PDF]
Heliyon, 2023 Introduction: There are few comparative studies on efficiency of broad range COVID19 vaccination strategy. This pilot aims to describe the effect of mixed COVID19 vaccination on vaccination adoption and subsequent total immunity, Conducted in Republic of
Igor Stoma +4 more
doaj +2 more sources
Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials [PDF]
The Lancet Regional Health. Americas, 2022 Summary: Background: Shortages of component two of Sputnik V vaccine (rAd5) are delaying the possibility of achieving full immunisation. The immunogenic response associated with the use of alternative schemes to complete the scheme was not explored ...
Alejandro Macchia +17 more
doaj +3 more sources